- Home
- SBFM vs LANC Comparison
SBFM vs LANC Comparison
Compare SBFM & LANC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- LANC
- Stock Information
- Founded
- SBFM 2006
- LANC 1961
- Country
- SBFM United States
- LANC United States
- Employees
- SBFM N/A
- LANC N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- LANC Packaged Foods
- Sector
- SBFM Health Care
- LANC Consumer Staples
- Exchange
- SBFM Nasdaq
- LANC Nasdaq
- Market Cap
- SBFM 4.9M
- LANC N/A
- IPO Year
- SBFM N/A
- LANC N/A
- Fundamental
- Price
- SBFM $1.55
- LANC $190.33
- Analyst Decision
- SBFM Strong Buy
- LANC Buy
- Analyst Count
- SBFM 1
- LANC 4
- Target Price
- SBFM $15.00
- LANC $211.33
- AVG Volume (30 Days)
- SBFM 4.3M
- LANC 170.7K
- Earning Date
- SBFM 05-19-2025
- LANC 04-30-2025
- Dividend Yield
- SBFM N/A
- LANC 1.99%
- EPS Growth
- SBFM N/A
- LANC 21.25
- EPS
- SBFM N/A
- LANC 5.69
- Revenue
- SBFM $34,874,283.00
- LANC $1,900,130,000.00
- Revenue This Year
- SBFM $192.48
- LANC $5.03
- Revenue Next Year
- SBFM N/A
- LANC $3.31
- P/E Ratio
- SBFM N/A
- LANC $33.60
- Revenue Growth
- SBFM 44.75
- LANC 1.77
- 52 Week Low
- SBFM $1.17
- LANC $163.20
- 52 Week High
- SBFM $33.60
- LANC $202.63
- Technical
- Relative Strength Index (RSI)
- SBFM 44.81
- LANC 61.99
- Support Level
- SBFM $1.17
- LANC $181.55
- Resistance Level
- SBFM $1.59
- LANC $193.40
- Average True Range (ATR)
- SBFM 0.19
- LANC 5.80
- MACD
- SBFM 0.03
- LANC 1.51
- Stochastic Oscillator
- SBFM 52.84
- LANC 86.29
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.